Update in polycystic ovary syndrome: New criteria of diagnosis and treatment in Japan

Reproductive Medicine and Biology

Volumn 12, Issue 3, 2013, Pages 71-77

  Kubota, Toshiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Diagnosis; Japan; New criteria; Polycystic ovary syndrome; Treatment

Indexed keywords

CLOMIFENE CITRATE; INSULIN; METFORMIN;

AMENORRHEA AND OLIGOMENORRHEA; CLINICAL FEATURE; EMBRYO TRANSFER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EXERCISE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; JAPAN; LIFESTYLE MODIFICATION; MULTIPLE PREGNANCY; OBESITY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; TRANSVAGINAL ECHOGRAPHY; WEIGHT REDUCTION; WITHDRAWAL BLEEDING;

EID: 84880035306     PISSN: 14455781     EISSN: 14470578     Source Type: Journal    
DOI: 10.1007/s12522-013-0145-1     Document Type: Review

References (59)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and feature of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.
2. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61.
3. Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.
4. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377-84.
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
6. The Japanese Society of Obstetrics and Gynecology (JSOG). Constitute of Reproductive rndocrinology. Reports of a new diagnostic criteria of PCOS in Japan. Acta Obstet Gynecol Jpn. 2007;59:868-86.
7. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod. 2003;18:2289-93.
8. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterol. 2007;132:2087-102.
9. Santoro N. Update in hyper- and hypogonadotropic amenorrhea. J Clin Endocrinol Metab. 2011;96:3281-8.
10. Deshmukh S. Polycystic ovarian syndrome. In: Allahbadia GN, editors. Infertility management made easy. Anshan Ltd: Tunbridge Wells; 2007. p. 172-97.
11. Dunaif A. Insulin resistance and the polycystic ovarian syndrome; mechanism and implications for pathogenesis. Endocrinol Rev. 1997;18:774-800.
12. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non obese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-9.
13. Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009;24:1548-55.
14. The Japanese Society of Obstetrics and Gynecology (JSOG). Constitute of reproductive endocrinology. Reports of a new treatment criteria of PCOS in Japan. Acta Obstet Gynecol Jpn. 2009;61:902-12.
15. Norman RJ, Davies MJ, Lord J, Moran IJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002;13:251-7.
16. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998;13:1502-5.
17. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36:105-11.
18. Teixerira PJ, Going SB, Houtkooper LB, Cussler EC, Metcalfe LL, Blew RM. Pretreatment predictors of attrition and successful weight management in women. Int J Obes Relat Metab Disord. 2004;28:1124-33.
19. Moran LJ, Pasquali RP, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the androgen excess and polycystic ovary syndrome society. Fertil Steril. 2009;92:1966-82.
20. Shepard MK, Balmaceda JP, Leija CG. Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril. 1979;32:641-5.
21. O'Herlihy C, Pepperell RJ, Brown JB, Smith MA, Sandri L, McBain JC. Incremental clomiphene therapy: a new method of treating persistent anovulation. Obstet Gynaecol. 1981;58:535-42.
22. Lobo RA, Gysler M, march CM, Goebelamann U, Mishell DR Jr. Clinical and laboratory predictors or clomiphene response. Fertil Steril. 1982;37:168-74.
23. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-66.
24. Neveu N, Granger L, St-Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril. 2007;87:113-20.
25. The ESHRE Capri workshop. Female infertility: treatment options for complicated cases. Hum Reprod. 1997;12:1191-6.
26. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009(4):CD002249.
27. Bracero N, Zacur HA. Polycystic ovary syndrome and hyperprolactinemia. Obst Gynecol Clin North Am. 2001;28:77-84.
28. Velazquez EM, Mendoza SG, Hamer T, Soga F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenaemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647-54.
29. Nestler JE, Stovall D, Alchter N, iuorno MJ, Jakubowicz MJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77:209-15.
30. Seli E, Duleba AJ. Optimizing ovulation induction in women with polycystic syndrome. Curr Opin Obstet Gynaecol. 2000;14:245-54.
31. Erhmann D, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Sturis J. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroid genesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-16.
32. Nestler JE, Jakubowics D. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075-9.
33. Kocak M, caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil steril. 2002;77:101-6.
34. Vandermolen DT, Ratts V, Evans WS, Stovall DW, Kauma SW, Nester JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patient with polycystic ovary syndrome who is resistant to clomiphene citrate alone. Fertil Steril. 2001;75:310-5.
35. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blind placebo-controlled trial. Hum Reprod. 2001;16:1625-31.
36. Sturrock NDC, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Pharmacol. 2002;53:469-73.
37. Kurabayashi T, Suzuki M, Kashima K, Banzai J, Terabayashi K, Fujita K, Tanaka K. Effects of low-dose metformin in Japanese women with clomiphene-resistant polycystic ovary syndrome. Reprod Med Biol. 2004;3:19-26.
38. Siebert TI, Kruger TF, Steyn DW, Nosarka S. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril. 2006;86:1432-7.
39. Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2000(4):CD000410.
40. Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulation hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril. 1995;63:729-33.
41. Nabot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-61.
42. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901-7.
43. Jain N. Laparoscopic surgery in infertility and gynecology. In: Gomel V editor. Ovarian drilling. Tunbridge Wells: Anshan Ltd; 2011. p 142-55.
44. Gjonnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril. 1984;41:20-5.
45. Farquhar CM, Williamson K, Gudex G, Johnson NP, Garland J, Sadler L. A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2002;78:404-11.
46. Farquhar C, Liford RJ, Marjoribanks J, Vandekerckhove P. Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane databases Syst Rev. 2007(3):CD001122.
47. Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod. 2002;17:2815-7.
48. Daniell JF, Miller W. Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril. 1989;51:232-6.
49. D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2007;CD002806.
50. Homburg R. Polycystic ovary syndrome: induction of ovulation. Baillieres Clin Endocrinol Metab. 1996;10:281-92.
51. Mulders AG, Laven JS, Imai B, Eijkemans MJ, Fauser BC. IVF outcome in anovulatory infertility (WHO group 2) - including polycystic ovary syndrome - following previous unsuccessful ovulation induction. Reprod Biomed Online. 2003;7:50-8.
52. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Frank S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotropin. Br J Obstet Gynaecol. 1992;99:128-31.
53. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:1086-91.
54. Wang JX, Davis MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001;16:2606-9.
55. D'Angelo A, Amso N: "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2002;CD002811.
56. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from unstimulated polycystic patients. Fertil Steril. 1994;62:353-62.
57. Morimoto Y. Cytoplasmic maturation and mitochondrial activity in human IVM. Abstract of the 16th world Congress on In Vitro Fertilization. In: Concurrent symposium C-14. 2011; p. 170, September Tokyo, Japan.
58. O'Connor KA, Ferrell R, Brindle E, Trumble B, Shofer J, Holman DJ, Weinstein M. Total and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomark Prev. 2009;18:828-36.
59. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:3327-34.